Slentrol

RSS

dirlotapide

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Slentrol has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 24/02/2015

Authorisation details

Product details
Name
Slentrol
Agency product number
EMEA/V/C/000116
Active substance
dirlotapide
International non-proprietary name (INN) or common name
dirlotapide
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QA08AB91
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
13/04/2007
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

15/01/2015 Slentrol - EMEA/V/C/000116 - IAIN/0007/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antiobesity preparations, excl. diet products

Therapeutic indication

As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight-management programme that also includes appropriate dietary changes and exercise practice.

Assessment history

How useful was this page?

Add your rating